Edwards Lifesciences announced it has received CE mark approval for the advanced Edwards Intuity Elite valve system. This next-generation rapid deployment system facilitates smaller incisions in surgical aortic valve implantation (AVI) procedures, and is built upon extensive evidence supporting the durability of the Carpentier-Edwards Perimount heart valve design.
JenaValve Technology announced that it has secured an expansion to its Series C venture round of US$10 million, increasing the total amount raised in the round from US$62.5 million to US$72.5 million.
The Boston Scientific Lotus valve system advanced transcatheter aortic valve implantation (TAVI) technology continued to demonstrate impressive performance at three months, according to new data presented at the American College of Cardiology conference 2014 in Washington, DC, USA.
CardioKinetix announced results of a pooled analysis study of the first-of-its-kind catheter-based Parachute ventricular partitioning device. Twelve-month clinical results from 111 consecutive US and European patients with ischaemic heart failure were presented at the 2014 American College of Cardiology (ACC) Conference in Washington, DC, USA, by Philip Adamson, medical director at the Heart Failure Institute at Oklahoma Heart Hospital.
The US Food and Drug Administration concludes that daily aspirin use can help ward off a heart attack or stroke in some people, but it is not for everyone.
It is well known that as a person ages, their risk of heart attack increases. But a new study suggests that, for individuals aged 65 and over, maintaining or increasing physical activity can reduce this risk and improve overall heart health.
After the UN General Assembly agreed to reduce deaths from the top four chronic diseases in 2011, the World Health Organization created targets for premature deaths from these diseases and their key risk factors. Now, research published in The Lancet reveals that reducing six modifiable risk factors to the agreed target levels could prevent over 37 million premature deaths over 15 years.
An international team of researchers in cooperation with the University of Bonn has taken two "snapshots" of a receptor which are of critical importance for blood coagulation. The scientists now hope to be able to develop novel drugs using these results. These include tailor-made blood-thinning substances for heart attack and stroke patients whose effects are reversible and better controllable than those of current therapies. The researchers are presenting their results in the renowned journal Nature.
A recent study—presented at the American Heart Association annual meeting (16–20 November, Dallas, USA) and published ahead of print in the Journal of the American Medical Association—found that early therapeutic hypothermia (prior to hospital; immediately after return of spontaneous circulation) does not improve survival or neurological function in patients who have survived a cardiac arrest. The principal investigator of the study, Francis Kim (Department of Medicine, School of Medicine, University of Washington, Seattle, USA) talks to Cardiovascular News about the role of pre-hospital therapeutic hypothermia for the management of patients who have survived a cardiac arrest.
The recently published FREEDOM trial randomised 1,900 diabetic patients with multivessel coronary artery disease and stable angina to coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI)2. At five years of follow-up, patients randomised to CABG had significantly lower mortality and myocardial infarction. These results were clinically meaningful, with an absolute event rate of the primary endpoint at five years of 18.7% in the CABG group and 26.6% in the PCI group.
Medtronic has revealed new data demonstrating positive outcomes for extreme risk patients with severe aortic stenosis who were treated with the CoreValve system via alternative access approaches. The data were unveiled during a late-breaking clinical session at the 94th American Association for Thoracic Surgery Annual Meeting.
Stentys has announced that the Journal of the American College of Cardiology (JACC) published a “State-of-the-Art Paper” entitled “Mechanisms, Pathophysiology, and Clinical Aspects of Incomplete Stent Apposition,” which highlights Stentys’ self-apposing stent among novel devices to minimise stent malapposition, also known as incomplete stent apposition, in clinical practice.
Medtronic has announced five-year follow-up data demonstrating the safety and performance of the Medtronic 3f Enable aortic bioprosthesis - the world’s first commercially available sutureless tissue heart valve.
Sorin Group has announced that it received US Food and Drug Administration (FDA) approval for the Mitroflow aortic pericardial heart valve with phospholipid reduction treatment.
Cardiosonic has announced CE marking of its TIVUS (therapeutic intravascular ultrasound) ablative catheter device.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos